Catalent has completed its $14 million expansion to increase the biologics packaging capabilities and capacity at its Bloomington, Indiana facility. The completed expansion adds 15,000 sqft of packaging infrastructure to the biologics and sterile manufacturing site, including five new packaging suites and a new quality control laboratory.
The company has developed strategic partnerships with industry leaders to bring new technologies and integrated capabilities to customers with three new state-of-the-art packaging lines, including an Optima combination syringe assembly machine, an automated Mikron auto-injector assembly machine, and a Dividella NeoTOP x (NTX) top-load cartoner with both semi-automated and fully-automated configurations.
All three high-speed lines are fully qualified and ready to provide customers faster and more flexible packaging solutions for vials, syringes, and devices with no glass-to-glass contact.
"The completion of this expansion marks a major milestone for our late-stage and commercial customers, allowing Catalent to focus on more complex device assembly and packaging needs for biologic products at higher volumes," said Mike Riley, Region President of Biologics North America. "This state-of-the-art equipment adds to our growing network of global packaging capabilities alongside our Brussels, Belgium, and Anagni, Italy drug product manufacturing sites."
This expansion was first announced in 2018.
Catalent's 875,000 sqft facility in Bloomington has deep expertise in sterile formulation and extensive biomanufacturing and drug product fill/finish capacity across liquid and lyophilised vials, prefilled syringes, and cartridges.
